Literature DB >> 32696989

Tetrandrine: a review of its anticancer potentials, clinical settings, pharmacokinetics and drug delivery systems.

Fei Luan1, Xirui He2, Nan Zeng1.   

Abstract

OBJECTIVES: Tetrandrine, a natural bisbenzylisoquinoline alkaloid, possesses promising anticancer activities on diverse tumours. This review provides systematically organized information on cancers of tetrandrine in vivo and in vitro, discuss the related molecular mechanisms and put forward some new insights for the future investigations. KEY
FINDINGS: Anticancer activities of tetrandrine have been reported comprehensively, including lung cancer, colon cancer, bladder cancer, prostate cancer, ovarian cancer, gastric cancer, breast cancer, pancreatic cancer, cervical cancer and liver cancer. The potential molecular mechanisms corresponding to the anticancer activities of tetrandrine might be related to induce cancer cell apoptosis, autophagy and cell cycle arrest, inhibit cell proliferation, migration and invasion, ameliorate metastasis and suppress tumour cell growth. Pharmaceutical applications of tetrandrine combined with nanoparticle delivery system including liposomes, microspheres and nanoparticles with better therapeutic efficiency have been designed and applied encapsulate tetrandrine to enhance its stability and efficacy in cancer treatment.
SUMMARY: Tetrandrine was proven to have definite antitumour activities. However, the safety, bioavailability and pharmacokinetic parameter studies on tetrandrine are very limited in animal models, especially in clinical settings. Our present review on anticancer potentials of tetrandrine would be necessary and highly beneficial for providing guidelines and directions for further research of tetrandrine.
© 2020 Royal Pharmaceutical Society.

Entities:  

Keywords:  anticancer; molecular mechanism; natural product; pharmaceutical applications; signalling pathway; tetrandrine

Mesh:

Substances:

Year:  2020        PMID: 32696989     DOI: 10.1111/jphp.13339

Source DB:  PubMed          Journal:  J Pharm Pharmacol        ISSN: 0022-3573            Impact factor:   3.765


  16 in total

1.  Tetrandrine Ameliorates Traumatic Brain Injury by Regulating Autophagy to Reduce Ferroptosis.

Authors:  Huan Liu; Shiqing He; Jianpeng Wang; Chong Li; Yongshi Liao; Qin Zou; Rui Chen
Journal:  Neurochem Res       Date:  2022-03-10       Impact factor: 3.996

Review 2.  Phytochemicals for the Prevention and Treatment of Renal Cell Carcinoma: Preclinical and Clinical Evidence and Molecular Mechanisms.

Authors:  Essa M Bajalia; Farah B Azzouz; Danielle A Chism; Derrek M Giansiracusa; Carina G Wong; Kristina N Plaskett; Anupam Bishayee
Journal:  Cancers (Basel)       Date:  2022-07-04       Impact factor: 6.575

3.  Identification of Hub Genes and Therapeutic Agents for IgA Nephropathy Through Bioinformatics Analysis and Experimental Validation.

Authors:  Ming Xia; Di Liu; Haiyang Liu; Liang Peng; Danyi Yang; Chengyuan Tang; Guochun Chen; Yu Liu; Hong Liu
Journal:  Front Med (Lausanne)       Date:  2022-06-28

4.  Plant Alkaloid Tetrandrine Is a Nuclear Receptor 4A1 Antagonist and Inhibits Panc-1 Cell Growth In Vitro and In Vivo.

Authors:  Hyo-Seon Lee; Dae Hwan Kim; In-Seon Lee; Ji-Hyun Park; Gregory Martin; Stephen Safe; Keuk-Jun Kim; Joung-Hee Kim; Byung Ik Jang; Syng-Ook Lee
Journal:  Int J Mol Sci       Date:  2022-05-09       Impact factor: 6.208

Review 5.  The Potential Anticancer Activity of Phytoconstituents against Gastric Cancer-A Review on In Vitro, In Vivo, and Clinical Studies.

Authors:  Sylwia Nakonieczna; Aneta Grabarska; Wirginia Kukula-Koch
Journal:  Int J Mol Sci       Date:  2020-11-05       Impact factor: 5.923

6.  Deciphering the molecular mechanism of tetrandrine in inhibiting hepatocellular carcinoma and increasing sorafenib sensitivity by combining network pharmacology and experimental evaluation.

Authors:  Biao Niu; Sidong Wei; Jianjun Sun; Huibo Zhao; Bing Wang; Guoyong Chen
Journal:  Pharm Biol       Date:  2022-12       Impact factor: 3.503

Review 7.  Traditional Herbal Medicine Discovery for the Treatment and Prevention of Pulmonary Arterial Hypertension.

Authors:  Zhifeng Xue; Yixuan Li; Mengen Zhou; Zhidong Liu; Guanwei Fan; Xiaoying Wang; Yan Zhu; Jian Yang
Journal:  Front Pharmacol       Date:  2021-11-09       Impact factor: 5.810

8.  Tetrandrine Suppresses Human Brain Glioblastoma GBM 8401/luc2 Cell-Xenografted Subcutaneous Tumors in Nude Mice In Vivo.

Authors:  Ching-Lung Liao; Yi-Shih Ma; Te-Chun Hsia; Yu-Cheng Chou; Jin-Cherng Lien; Shu-Fen Peng; Chao-Lin Kuo; Fei-Ting Hsu
Journal:  Molecules       Date:  2021-11-24       Impact factor: 4.411

9.  Tetrandrine Prevents Neomycin-Induced Ototoxicity by Promoting Steroid Biosynthesis.

Authors:  Qilei Zhang; Yunhao Wu; Yan Yu; Yuguang Niu; Qiaojun Fang; Xin Chen; Jieyu Qi; Chen Zhang; Geping Wu; Kaiming Su; Renjie Chai
Journal:  Front Bioeng Biotechnol       Date:  2022-04-20

10.  Tetrandrine suppresses the growth of human osteosarcoma cells by regulating multiple signaling pathways.

Authors:  Nan Wang; Shengdong Yang; Tao Tan; Yanran Huang; Yangmei Chen; Chaoqun Dong; Jin Chen; Xiaoji Luo
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.